Archivio delibere
Deliberazione n.136 del 26/01/2017
Autorizzazione all’addendum 1 al contratto per lo studio: “A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID”. Codice Protocollo CAMN107AIC05. Responsabile: Dr. Emilio Usala, Sponsor: Novartis Farma S.p.A. CRO: Opis s.r.l. – U.O.C. Ematologia e Centro Trapianti Midollo Osseo – P.O. Businco
Autorizzazione all’addendum 1 al contratto per lo studio: “A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID”. Codice Protocollo CAMN107AIC05. Responsabile: Dr. Emilio Usala, Sponsor: Novartis Farma S.p.A. CRO: Opis s.r.l. – U.O.C. Ematologia e Centro Trapianti Midollo Osseo – P.O. Businco
Data seduta:26/01/2017
In pubblicazione dal: 27/01/2017-al: 11/02/2017
In pubblicazione dal: 27/01/2017-al: 11/02/2017